news Universal flu vaccine protects against influenza A and B viruses 29 August 2022 | By Ria Kakkad (Drug Target Review) Vaccinating mice with this universal flu candidate induced broad neuraminidase inhibition, M2 ectodomain specific antibodies and T cell immune responses.
news Janssen licenses its pan-influenza antibody to Leyden Labs 20 January 2022 | By Victoria Rees (Drug Target Review) Janssen's monoclonal antibody CR9114, for the potential treatment of influenza, has been exclusively licensed by Leyden Labs for development and commercialisation.